RFP 22-010: USAID PMI Uganda Malaria Reduction Activity – Malaria Therapeutic Efficacy Study in Uganda
A study on the efficacy and safety of artemether-lumefantrine, pyronaridine- Artesunate, Artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in children in Uganda
John Snow, Inc. (herein referred to as “JSI”) is soliciting proposals for the supply and delivery of A study on the efficacy and safety of artemether-lumefantrine, pyronaridine- Artesunate, Artesunate-amodiaquine and dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in children in Uganda. This procurement is funded by the United States Agency for International Development (USAID) and is subject to all applicable Federal Acquisition Regulations (FAR) and AID Acquisition Regulation (AIDAR).
Please submit your most competitive proposal in accordance with the instructions and product specifications. Any award issued as a result of this RFP will be subject to all instructions, product specifications, certifications and terms and conditions included in this RFP. All submissions should be sent to procurement_pumra@jsi.com.
RFP 22-010 Therapeutic Efficacy Test Study
Budget Template
Budget Notes
Issuance Date: May 27, 2022
Deadline for Questions: June 06, 2022, 5:00 PM GMT
Deadline: June 13, 2022, 5:00 PM GMT